Cardiovasculars

Product Details:

Indications:

• Management of hypertension.
• Management of angina pectoris.
• Management of cardiac dysrhythmias.
• Management of myocardial infarction. Early intervention in the acute phase and long term prophylaxis after recovery from myocardial infarction

Dosage:

Angina Pectoris:

• Most patients with angina pectoris will respond to a dose of 100 mg daily. This is most conveniently administered as a single 100 mg tablet once daily, which may if desired be given in the form of one 50 mg tablet twice daily. It is unlikely that any additional benefit will be gained by increasing the dose.

Hypertension:

• Most patients will respond to a dose of 100 mg once daily. This is most conveniently administered as a single 100 mg tablet once daily. It is unlikely that any additional benefit will be gained by increasing the dosage.
• In refractory cases a further reduction of blood pressure may be achieved by combining Atenolol Tablets with other anti-hypertensive agents.  Atenolol Tablets may be combined with a diuretic.
• Patients can be transferred to Atenolol Tablets from other anti-hypertensive treatments. Caution should be excercised when transferring a patient from clonidine. The withdrawal of clonidine may result in the release of large amounts of catecholamines which may give rise to a hypertensive crisis. If Atenolol Tablets are administered in these circumstances, the unopposed alpha-receptor stimulation may potentiate this effect.

Product Details:

Indication

• Adrenaline is a direct-acting sympathomimetic agent.
• Adrenaline may be used to provide rapid relief of severe hypersensitivity reaction to drugs and other allergens, and in the emergency treatment of anaphylactic shock.

Dosage

• Severe hypersensitivity reactions, anaphylactic shock

IM Injection

• Adults The usual dose is 500 micrograms (0.5ml of adrenaline 1/1000). If necessary, this dose may be repeated several times at 5-minute intervals according to blood pressure, pulse and respiratory function.
• Half doses of adrenaline may be safer for patients who are taking amitriptyline, imipramine or a beta blocker.

Paediatric population

The following doses of adrenaline 1/1,000 are recommended

If necessary, these doses may be repeated at 5-15 -minute intervals according to blood pressure, pulse and respiratory function.

Product Details:

Indications:  

• Chronic stable angina
• Hypertension
• Acute Myocardial Infarction
• Coronary heart disease

Dosage:

Oral:

• Chronic stable angina, Hypertension.
• Adult: Per tablet contains Atenolol 25 or 50 mg and Amlodipine (as Besylate) 5 mg: 1 tab once daily, may increase to 2 tablets daily if needed.
• Elderly: Per tablet contains Atenolol 25 mg and Amlodipine (Besylate) 5 mg: Initiate with 1 tablet daily.
• Renal impairment: Per tablet contains Atenolol 25 mg and Amlodipine (Besylate) 5 mg: Initiate with 1 tablet daily.

Product Details:

Indications:

• Amlodipine is used to lower your blood pressure. It can be used alone or in combination with other heart medications.
• Amlodipine is also used to help blood flow more easily to your heart when the arteries in your heart are blocked.

Product Details:

Indications:

Congestive heart failure (treatment)-

• amrinone is indicated for the short-term management of congestive heart failure in patients who have not responded adequately to digitalis, diuretics, and/or vasodilators.

Dosage:

Congestive Heart Failure:

• Load: 0.75 mg/kg IV bolus over 2-3 minutes, THEN
• 5-10 mcg/kg/min IV
• Total daily dose (including loading dose) should not exceed 10 mg/kg/day
• Therapeutic dosage range: 0.5-7 mcg/mL

Renal Impairment:

• CrCl <10 mL/min: Administer 50-75% of the dose
• CrCl ≥10 mL/min: Dosage adjustment not required

Product Details:

Indications:

• Prophylactic reduction of perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass during repeat coronary artery bypass graft surgery or in selected patients undergoing initial coronary artery bypass graft surgery for whom the risk of bleeding is high because of impaired hemostasis or for whom transfusion is unavailable or unacceptable; surgery on aortic arch.

Dosage:

• Adults: Usual test dose is 10,000 kallikrein inactivator units (KIU) (1.4 mg) I.V. If no adverse reactions occur within 10 minutes, give loading dose of 2 million KIU (280 mg) I.V. over 20 to 30 minutes while the patient is supine, after induction of anesthesia but before sternotomy. Follow loading dose with continuous I.V. infusion of 500,000 KIU/hour (70 mg/hour). Before cardiopulmonary bypass starts, 2 million KIU (280 mg) of aprotinin should be added to the priming fluid of the cardiopulmonary bypass circuit by replacement of an aliquot of the priming fluid.
•  If an allergic reaction occurs during injection or infusion of aprotinin, drug administration should be discontinued immediately. Severe acute hypersensitivity reactions should be treated immediately with appropriate therapy (for example, epinephrine, corticosteroids, maintenance of adequate airway, oxygen, I.V. fluids, antihistamines, maintenance of blood pressure), as indicated.

Product Details:

Indications:

• ATORVINE (Atorvastatin) lowers cholesterol in your blood. It lowers the "bad" cholesterol and triglycerides in your blood. It can raise your "good" cholesterol as well. It is for adults and children over 10 whose cholesterol does not come down enough with exercise and a low-fat diet alone.

Dosage:

• The recommended starting dose of ATORVINE Tablets in adult patients is 10 or 20 mg once daily. Patients that require large Low-Density-Lipoprotein cholesterol (LDL-C) reduction (>45%) can start at 40 mg once daily. The recommended starting dose for pediatric patients is 10 mg once daily; maximum recommended dose: 20 mg once daily.

Product Details:

Indications:  

• Mixed dyslipidaemia.

Dosage:

• Adult: Per tablet contains atorvastatin 10 mg and fenofibrate (micronised) 160 mg: 1 tab once daily.

Product Details:

Indications:

• Bisoprolol is indicated in the treatment of hypertension, angina and heart failure. It may be used alone or in combination with other antihypertensive agents.

Dosage:

• The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
• For heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily.

Product Details:

Indications:

• Hypertension
• Congestive heart failure
• Myocardial Infarction
• Captopril can be used alone or in combination with other antihypertensive agents

Dosage:

CHF and arrhythmias

Adult:

• Take 1hr before meals. Heart failure: initially 25mg 3 times daily (generally with diuretic and digitalis regimen). Increase, if needed, to 50mg 3 times daily. After 2 wks, may increase; max 450mg/day. Salt/volume depleted, or if systolic BP <100mmHg: initially 6.25mg or 12.5mg 3 times daily. Titrate to usual dose after several days. Post-MI: first dose 6.25mg 3 days post-MI, then increase to 12.5mg 3 times daily. Increase to 25mg 3 times daily over several days; maintenance 50mg 3 times daily.

Diabetes:

• Diabetic nephropathy (proteinuria >500mg/day) in type 1 diabetes with retinopathy.

Adult:

• Take 1 hr before meals. 25mg 3 times daily. Renal impairment: see full labeling.

 
Hypertension

Adult:

• Take 1 hr before meals. Initially 25mg 2–3 times daily. After 1–2 wks may increase to 50mg 2–3 times daily. If control unsatisfactory, see literature. Titrate to usual dose after several days. Monitor closely for 1st 2 wks and if dose increased; max 450mg/day. Renal impairment: see full labeling.

Product Details:

Indications:

• Dobutamine Hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. Dobutamine Hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema.

Dosage:

Adult Dose:

• I.V. Infusion administered at a rate of 2.5 to 15mcg/kg of body weight/minute upto 40mcg/kg/minute.
• Paediatric: Not recommended.
• Renally Impaired Patients: Not known, administer with caution.

Product Details:

Indications:

• Enalapril oral tablet is used to treat high blood pressure, heart failure, and asymptomatic left ventricular dysfunction.

Dosage:
The dosage of Enalapril Maleate Tablets for various indications is given below:

Treatment of Hypertension in Adults:

• The recommended initial dose is 5 mg once daily. The normal maintenance dose is one 20 mg tablet taken once daily. The dosage should be adjusted according to the requirements of the individual patient to a maximum of 40 mg daily.

Treatment of Hypertension in Pediatrics:

• The recommended initial dose dose is 0.08 mg/kg (up to 5 mg) once daily.

Treatment of Renovascular Hypertension:

• Since blood pressure and renal function in such patients may be specially sensitive to ACE inhibition, the treatment should be started with a lower starting dose in the range of 2.5 mg to 5 mg. The dosage should then be adjusted to meet the treatment objectives of the patient. Caution is recommended in treating patients with hypertension who have been treated recently with diuretics.

Product Details:

Indications:

Esmolol Hydrochloride is a beta-adrenergic blocker used for the short-term treatment of:

• Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia
• Control of perioperative tachycardia and hypertension

Dosage:

• Adult: IV- Arrhythmias- As HCl: Loading dose: 500 mcgkg; Maintenance: 50 mcgkgmin for 4 minutes. If response is unsatisfactory within the 1st 5 minutes, give 2nd loading dose of 500 mcgkg, then maintenance infusion at 100 mcgkgmin for 4 minutes. Perioperative HTN andor tachycardia during anesthesia: Loading dose: 80 mg, then 150 mcgkgmin via infusion, up to 300 mcgkgmin if needed. After anesthesia: Infuse 500 mcgkgmin for 4 minutes, and then infuse at 300 mcgkgmin if needed. Postoperative: Loading dose: 500 mcgkg, maintenance: 50 mcgkgmin for 4 minutes. It comes as a solution for injection, to be administered by a healthcare provider into the vein.

Product Details:

Indications:

• Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
• Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
• Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Dosage:

Hypertension:

• Adult: Initially, 12.5 mg, may increase to 25-50 mg once daily as necessary either alone or w/ other antihypertensives.
• Child: <6 mth 1-3 mg/kg/day in 1-2 divided doses. Max: 37.5 mg daily; 6 mth to 2 yr 1-2 mg/kg/day in 1-2 divided doses. Max: 37.5 mg daily; >2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.
• Elderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.

Oral

Oedema:

• Adult: 25-100 mg daily in 1-2 divided doses or intermittently on alternate days or on 3-5 days a wk.
• Child: <6 mth 1-3 mg/kg/day in 1-2 divided doses. Max: 37.5 mg daily; 6 mth to 2 yr 1-2 mg/kg/day in 1-2 divided doses. Max: 37.5 mg daily; >2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.
• Elderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.

Product Details:

Indications:

• Treatment of essential hypertension.
• This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

Dosage:

• Irbesartan/ Hydrochlorothiazide can be taken once daily, with or without food.
• Irbesartan/ Hydrochlorothiazide 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
• Irbesartan/ Hydrochlorothiazide 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan/ Hydrochlorothiazide 150 mg/12.5 mg.
• Irbesartan/ Hydrochlorothiazide 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan/ Hydrochlorothiazide 300 mg/12.5 mg.
• Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. When necessary, Irbesartan/ Hydrochlorothiazide may be administered with another antihypertensive medicinal product .

Product Details:

Indications:

• Irbesartan is used to lower your blood pressure. It’s also used to help your kidneys function better if you have if you have diabetic nephropathy from type 2 diabetes.

Dosage:

Hypertension:

• Adult: 150 mg once daily, may increase to 300 mg once daily if needed. Patient w/ intravascular volume depletion: Initially, 75 mg once daily.
• Elderly: >75 yr Initially, 75 mg once daily.
• Renal impairment: Haemodialysis: Initially, 75 mg once daily.
• Diabetic nephropathy in Type 2 diabetes mellitus:
• Adult: Initially, 150 mg once daily, may increase to 300 mg once daily if needed.

Product Details:

Indications: 

• Hypertension
• Heart Failure
• Acute Myocardial Infarction
• Renal Complications of Diabetes Mellitus

Dosage:

Hypertension:

• Adult: Initially, 5-10 mg daily given at bedtime to avoid precipitous fall in BP. Patient with renovascular hypertension, volume depletion, severe hypertension: Initially, 2.5-5 mg once daily. Patient on diuretic: Initially, 5 mg once daily. Maintenance: 20 mg once daily, up to 80 mg daily may be used if needed.
• Child: ≥6 years: Initially, 0.07 mg/kg (up to 5 mg once daily). Adjust dose until desired BP goal is achieved.
• Renal impairment: Adult: Dialysis: Initially 2.5 mg once daily. Max dose: 40 mg once daily.

Heart failure:

• Adult: As adjunctive therapy: Initially, 2.5 mg daily. Maintenance: 5-40 mg daily as a single dose.

Post myocardial infarction:

• Adult: Initially, 5 mg once daily for 2 days started within 24 hours of the onset of symptoms. Increase to 10 mg once daily. Patients with low systolic BP: Initially, 2.5 mg once daily.

Diabetic nephropathy;

• Adult: For hypertensive type 2 diabetics with microalbuminuria: 10 mg once daily, may increase to 20 mg once daily to achieve a sitting diastolic BP <90 mmHg.

Product Details:

Indications:

• For the treatment of hypertension, for patients in whom combination therapy is appropriate.

Dosage:

• Usual initial and maintenance adult dose: 1 tablet once daily.

For patients who do not respond adequately, adjust to a maximum dose of:

• 1 tablet of LOSZIDE 100 mg/ 25 mg FDC (Fixed Dose Combination) daily or,
• 2 tablets of LOSZIDE 50 mg/ 12.5 mg FDC (Fixed Dose Combination) daily

Product Details:

Indications:

Losartan is used for three main purposes. It’s used to:

• Treat high blood pressure
• Reduce your risk of a stroke if you have high blood pressure and left ventricular hypertrophy (LVH), a condition that causes the walls in the heart’s left ventricle to thicken
• Treat diabetic nephropathy, which is kidney disease caused by diabetes

Dosage:

Hypertension

• Adult: 50 mg once daily, increased to 100 mg daily as a single dose or in 2 divided doses if needed.
• Child: ≥6 years: Initially 700 mcg/kg increased to a maximum of 50 mg once daily if needed.
• Elderly: >75 years: Initally, 25 mg once daily.

Diabetic nephropathy in Type 2 diabetes mellitus
Adult: 50 mg once daily, increased to 100 mg daily as a single dose or in 2 divided doses if needed.
Elderly: >75: Initially 25 mg once daily.

Renal impairment:
Special Populations

• Patients with intravascular fluid depletion: Initially, 25 mg once daily.

Product Details:

Indications:

• Hypertension
• Salt and water retention

Dosage:

• Hypertension : 2.5-5 mg OD
• Salt and water retention : 5-20 mg OD

Dosage Adjustment:

• Renal Impairment: May be required.
• Hepatic Impairment: May be required.

Product Details:

Indications:

• Hypertension
• Angina pectoris

Dosage:

• Dosage should be individualized. The recommended initial dose is one tablet once daily. If necessary, the dose may be increased to two tablets once daily.
• Small, fragile or elderly individuals, or patients with hepatic insufficiency can be initiated on separate tablets of metoprolol extended-release and amlodipine 2.5 mg both once daily. The dose of amlodipine can be increased to 5 mg once daily depending on the patient tolerability. When the patient is stabilized on this dose he/she can be shifted to one tablet once daily.

Product Details:

Indications:

• Hypertension
• Angina Pectoris
• Heart Failure

Dosage:

Hypertension:

• Adult: Conventional preparation: Initially, 50-100 mg daily in single or 2 divided doses; may increase wkly to 400 mg daily depending on response. Maintenance: 100-200 mg daily; up to 400 mg daily. Extended-release preparation: 25-100 mg once daily. Hepatic impairment: Reduce dose.

Angina pectoris:

• Adult: 50-100 mg bid-tid. Hepatic impairment: Reduce dose.

Cardiac arrhythmias:

• Adult: 50 mg bid-tid; increased to 300 mg daily in divided doses if needed. Hepatic impairment: Reduce dose.

Adjunct in hyperthyroidism:

• Adult: 50 mg 4 times daily. Hepatic impairment: Reduce dose.

Prophylaxis of migraine:

• Adult: 100-200 mg daily in divided doses. Hepatic impairment: Reduce dose.

Stable symptomatic heart failure:

• Adult: As a modified-release preparation of metoprolol succinate: Initially, 12.5-25 mg of equivalent metoprolol tartrate dose. Increase, as tolerated, at 2-weeks intervals to a max of 20 mg once daily. Hepatic impairment: Reduce dose.

Product Details:

Indications:

• Hypertension.
• Angina pectoris.
• Cardiac arrhythmias (especially supraventricular tachyarrhythmias).
• As an adjunctive treatment of thyrotoxicosis.
• Prophylaxis of migraine.

Dosage:

Hypertension:

• Adult: Conventional preparation: Initially, 50-100 mg daily in single or 2 divided doses; may increase wkly to 400 mg daily depending on response. Maintenance: 100-200 mg daily; up to 400 mg daily. Extended-release preparation: 25-100 mg once daily. Hepatic impairment: Reduce dose.

Angina pectoris:

• Adult: 50-100 mg bid-tid. Hepatic impairment: Reduce dose.

Cardiac arrhythmias:

• Adult: 50 mg bid-tid; increased to 300 mg daily in divided doses if needed. Hepatic impairment: Reduce dose.

Adjunct in hyperthyroidism:

• Adult: 50 mg 4 times daily. Hepatic impairment: Reduce dose.

Prophylaxis of migraine:

• Adult: 100-200 mg daily in divided doses. Hepatic impairment: Reduce dose.

Stable symptomatic heart failure:

• Adult: As a modified-release preparation of metoprolol Succinate: Initially, 12.5-25 mg of equivalent metoprolol tartrate dose. Increase, as tolerated, at 2-weeks intervals to a max of 20 mg once daily. Hepatic impairment: Reduce dose.

Product Details:

Indications:

• Hypertension
• Prophylaxis of chronic stable angina pectoris.

Dosage:

• The recommended starting dose is 10 mg every 12 hours swallowed with water with subsequent titration of dosage according to response.
• Permit titration of the initial dosage, which may be adjusted to 40 mg every 12 hours, to a maximum daily dose of 80 mg.
• Co-administration with CYP 3A4 inhibitors or CYP 3A4 inducers may result in the recommendation to adapt the nifedipine dose or not to use nifedipine at all .

Method of administration:

• Oral use.
• As a rule, tablets are swallowed whole with a little liquid, either with or without food.It should not be taken with grapefruit juice .

Duration of treatment:

• Treatment may be continued indefinitely.

Additional information on special populations:

• Older people (> 65 years)
• The pharmacokinetics of nifedipine are altered in older people so that lower maintenance doses of nifedipine may be required compared to younger patients.

Product Details:

Indications:

• Nitroglycerin in 5% Dextrose Injection is indicated for treatment of peri-operative hypertension;
• For control of congestive heart failure in the setting of acute myocardial infarction.
• For treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β-blockers; and for induction of intraoperative hypotension

Dosage:

Unstable angina:

• Adult: Initially, 5-10 mcg/minute. Usual range: 10-200 mcg/minute.

Heart failure:

• Adult: Initially, 5-25 mcg/minute.

Acute myocardial infarction:

• Adult: Initially, 5-25 mcg/minute, adjust according to patient's response. Usual range: 10-200 mcg/minute. Max: 400 mcg/minute.

Induction of hypotension or control of hypertension during surgery:

• Adult: Initially, 5-25 mcg/minute, adjust according to patient's response. Usual range: 10-200 mcg/minute. Max: 400 mcg/minute.

Product Details:

Indications:

• Indicated for use as an emergency measure in the restoration of blood pressure in cases of acute hypotension.
• For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions).
• As an adjunct in the treatment of cardiac arrest and profound hypotension.

Dosage:

• Acute hypotensive states
• Adult: Initially, 8-12 mcg/minute, up to 8-30 mcg/minute in refractory shock.
• Infuse using a solution of 4 mcg/ml in glucose 5%, or sodium chloride 0.9% and glucose 5% at a rate of 2-3 ml/minute. Adjust according to BP response. Average maintenance dose: 0.5-1 ml/minute (2-4 mcg/minute). Infuse via a central venous catheter or into a large vein.
• Child: Administer at a rate of 2 mcg/minute. Alternatively, 2 mcg/m2/minute.
• Adjust rate according to BP response and perfusion.
• Elderly: Initial dose should be at low end of dose range.
• Upper gastrointestinal haemorrhage.
• Adult: Intraperitoneal admin: 8 mg in 250 ml of 0.9% sodium chloride injection. Alternatively, instill 8 mg in 100 ml of 0.9% sodium chloride solution through a nasogastric tube every hr for 6–8 hours, then every 2 hours for 4–6 hours.
• Withdraw drug gradually.
• Dilute with 5% glucose inj, with or without sodium chloride; dilution with sodium chloride inj alone is not recommended.

Product Details:

Indications:

• Hypertension
• Congestive heart failure
• Raynaud's phenomenon and Raynaud's disease
• Benign prostatic hyperplasia

Dosage:

Hypertension:

• Adult: As hydrochloride: Initially, 500 mcg bid-tid for 3-7 days, increased to 1 mg bid-tid for the next 3-7 days if tolerated, and gradually increased thereafter according to patient's response. Max dose: 20 mg daily.

Heart failure:

• Adult: As hydrochloride: Initially, 500 mcg bid-qid, gradually increased according to response.
• Maintenance: 4-20 mg daily.

Raynaud's syndrome:

• Adult: Initially, 500 mcg bid, increased to a maintenance dose of ≤2 mg bid.

Benign prostatic hyperplasia:

• Adult: Initially, 500 mcg bid, increased to a maintenance dose of ≤2 mg bid.

Product Details:

Indications:

• Ramipril is in a group of drugs called ACE inhibitors. ACE stands for angiotensin converting enzyme.
• Ramipril is used to treat high blood pressure (hypertension) or congestive heart failure, and to improve survival after a heart attack.

Dosage:

• Person diagnosed with hypertension is generally prescribed dose of the drug between 2.5 to 20 mg. The dose for a person suffering from kidney disease is generally low. Heart failure patients in the beginning are normally given a dose between 1.25 to 2.5 mg taken two times every day. Dose of the drug may vary person to person depending upon the severity of the disease. Therefore dosage of the drugs should be taken the same way that your doctor has prescribed.

Product Details:

Indications:

• Hyperlipidemia and Mixed Dyslipidemia
• Hypertriglyceridemia
• Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)
• Homozygous Familial Hypercholesterolemia
• Slowing of the Progression of Atherosclerosis
• Primary Prevention of Cardiovascular Disease

Dosage:

• Primary prevention of cardiovascular disease; adjunct to diet for hyperlipidemia, mixed dyslipidemia,hypertriglyceridemia, primary dysbetalipoproteinemia (type III hyperlipoproteinemia); slowing of progression ofatherosclerosis
• Adults: 5 to 40 mg P.O. daily. Use 40-mg dose only for patients not reaching LDL-C goal with 20 mg.
• ¿¿¿ Homozygous familial hypercholesterolemia
• Adults: 20 mg/day P.O. daily. (Response to therapy should be estimated from preapheresis LDL-C levels.).
• ¿¿¿ Heterozygous familial hypercholesterolemia after failure of an adequate trial of diet therapy
• Children ages 10 to 17: 5 to 20 mg P.O. daily. Maximum recommended dosage is 20 mg/day. Individualize dosagesaccording to recommended goal of therapy. Make adjustments at intervals of 4 weeks or more.

Product Details:

Indications:

• Hypercholesterolaemia
• Cardiovascular prevention

Dosage:

Hyperlipidaemias:

• Adult: Initially, 10-20 mg/day, to be taken in the evening. May start with 40 mg once daily in patients with high CV risk or require a large reduction in cholesterol. For patients with moderate CV risk, initiate with 10 mg once daily. May adjust dose at intervals of at least 4 weeks. Max: 80 mg once daily. For patients with homozygous familial hypercholesterolaemia: 40 mg once daily in the evening or 80 mg daily (given in 3 divided doses of 20 mg, 20 mg and an evening dose of 40 mg).
• Renal impairment: Severe impairment: initially, 5 mg once daily. Doses >10 mg daily should be used with caution.

Cardiovascular risk reduction:

• Adult: In high-risk patients (e.g. patients with diabetes mellitus or atherosclerotic cardiovascular disease): 20-40 mg once daily. Moderate-risk patients: 10 mg once daily.

Special Populations:

• For patients taking drugs that interact with simvastatin, initially, 5 mg once daily.
• Max: 10 mg/day (for patients taking ciclosporin, fibrates or nicotinic acid) and 20 mg/day (for patients taking amiodarone or verapamil).

Product Details:

Indications:

• Biofactor Streptokinase is indicated in adults.
• Acute myocardial infarction: within 12 hours of onset with persistent ST-segment elevation or recent left bundle-branch block.

Dosage:

Adults:

• Systemic administration: A single dose of 1.5 million IU streptokinase should be infused intravenously over one hour.
• Local intracoronary administration: A bolus of 20,000 IU streptokinase should be followed by a maintenance infusion of 2,000 IU to 4,000 IU per minute over 30 to 90 minutes depending on the achievement of coronary artery patency.

Method of Administration:

• The administration of streptokinase may be intravenous or intracoronary.
• For instructions on reconstitution of the medicinal product before administration.
• Upon reconstitution with physiological saline a clear solution, colourless to yellowish, is obtained.

Note: When thrombolytic therapy is necessary and a high antibody concentration against streptokinase is present or when recent streptokinase therapy has been given (more than 5 days and less than one year previously), homologous fibrinolytics should be used.

Adjuvant treatment:

• Treatment with aspirin (150 mg daily) for at least 4 weeks is recommended for prophylaxis after streptokinase therapy for acute myocardial infarction. The first dose should be given as soon as possible after the myocardial infarction.

Product Details:

Indications:

• Treatment of essential hypertension.
• Telmisartan/Hydrochlorothiazide fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.

Dosage:

• Telmisartan/Hydrochlorothiazide should be taken in patients whose blood pressure is not adequately controlled by telmisartan alone. Individual dose titration with each of the two components is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed combination may be considered.
• Telmisartan/Hydrochlorothiazide 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 40 mg

Renal impairment:

• Periodic monitoring of renal function is advised

Hepatic impairment:

• In patients with mild to moderate hepatic impairment the posology should not exceed Telmisartan/Hydrochlorothiazide 40 mg/12.5 mg once daily. Telmisartan/Hydrochlorothiazide is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function

Elderly:

• No dose adjustment is necessary.

Paediatric population:

• The safety and efficacy of Telmisartan/Hydrochlorothiazide in children and adolescents aged below 18 have not been established. No data are available.

Method of administration:

• Telmisartan/Hydrochlorothiazide tablets are for once-daily oral administration and should be taken with liquid, with or without food.
• Precautions to be taken before handling or administering the medicinal product
• Telmisartan/Hydrochlorothiazide should be kept in the sealed blister due to the hygroscopic property of the tablets. Tablets should be taken out of the blister shortly before administration

Product Details:

Indications:

• Telmisartan tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Dosage:

• Dosage must be individualized. The usual starting dose of Telmisartan tablets is 40 mg once a day. Blood pressure response is dose related over the range of 20-80 mg

Special Populations:

• Patients with depletion of intravascular volume should have the condition corrected or Telmisartan tablets should be initiated under close medical supervision Patients with biliary obstructive disorders or hepatic insufficiency should have treatment started under close medical supervision.
• Most of the antihypertensive effect is apparent within two weeks and maximal reduction is generally attained after four weeks. When additional blood pressure reduction beyond that achieved with 80 mg Telmisartan tablets is required, a diuretic may be added.
• No initial dosing adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
• Telmisartan tablets may be administered with other antihypertensive agents.
• Telmisartan tablets may be administered with or without food.

Product Details:

Indications:

Terazosin tablets are indicated for:

• The treatment of mild to moderate hypertension
• The symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH).

Dosage:

Hypertension:

• Adult: Initially, 1 mg at bedtime, gradually increased at 7-day intervals according to patient's response. Maintenance: 2-10 mg once daily. Max: 20 mg/day in 1 or 2 divided doses.
• Max Dosage: 20 mg daily in a single or 2 divided doses.

Benign prostatic hyperplasia:

• Adult: 1 mg at bedtime gradually increased at 7-day intervals according to patient's response. Maintenance: 5-10 mg once daily. Max: 20mg daily.

Product Details:

Indications:

• Is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs.

Dosage:

Adult:

• Hypertension: Per combination tablet contains valsartan/ hydrochlorothiazide: 80/12.5 mg; 160/12.5 mg; 160/25 mg; 320/12.5 mg; 320/25 mg: Initially, 80/12.5 mg once daily, titrate dose gradually according to response, up to 320/25 mg.

Method of administration:

• Valsartan/Hydrochlorothiazide 80mg/12.5mg Film coated Tablets can be taken with or without food and should be administered with water.

Product Details:

Indications:

• Indicated for the treatment of paroxysmal supraventricular tachycardia and the reduction of ventricular rate in atrial flutter/fibrillation.

 
Dosage:

For slow intravenous injection:

• Adults: 5-10 mg by slow intravenous injection over a period of 2 minutes. The patient should be observed continuously, preferably under ECG and blood pressure control. If necessary, e.g. in paroxysmal tachycardia, a further 5 mg may be given after 5 to 10 minutes.
• Children: must always be administered under ECG monitoring in young patients.
• 0-1 year: 0.1-0.2 mg/kg bodyweight (usual single dose range: 0.75-2 mg).
• 1-15 years: 0.1-0.3 mg/kg bodyweight (usual single dose range: 2-5 mg).
• The dose may be repeated after 30 minutes if necessary. Many cases are controlled by doses at the lower end of the range. The injection should be stopped at the onset of the desired effect.
• Elderly: The dosage should be administered over 3 minutes to minimise the risk of adverse effects.
• Dosage in impaired liver and renal function: Significant hepatic and renal impairment should not increase the effects of a single intravenous dose but may prolong its duration of action.